Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Granules India hits 52-week high after USFDA approval

Colchicine tablets are used in the treatment of Familial Mediterranean Fever.

February 06, 2020 / 10:02 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Granules India share price touched 52-week high of Rs 162 adding nearly 6 percent intraday on February 6 after the pharma company received USFDA approval for Colchicine Tablets.

The US Food & Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc, a wholly-owned foreign subsidiary of the company for Colchicine Tablets USP, 0.6 mg.

It is bioequivalent of the reference-listed drug product (RLD), Colcrys Tablets, 0.6 mg, of Takeda Pharmaceuticals USA, Inc.

This marks the first Paragraph 4 application from Granules.

Colchicine tablets are used for the treatment of Familial Mediterranean Fever (FMF).

At 0949 hours, Granules India was quoting at Rs 161.20, up Rs 7.40, or 4.81 percent, on the BSE.

Moneycontrol News
first published: Feb 6, 2020 10:02 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347